TPST · Tempest Therapeutics, Inc. · Proposed Sales
$0.81
+0.01 (+0.63%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We expect that our existing cash and cash equivalents will fund our projected operating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued. Accordingly, there is substantial doubt regarding our ability to continue as a going concern for a period of 12 months from the date of the issuance of the Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 13, 2026
Market Cap
$12.28M
Shares
14.81M
Volume · Oct 2
2.27M
Avg daily vol (3M)
2.59M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2024-08-13 | Versant Venture Capital VI, L.P. | Owner | 387,999 | 2024-08-12 | Jones Trading Institutional Services LLC |
| 2024-08-09 | Versant Venture Capital VI, L.P. | 10% Stockholder | 400,000 | 2024-08-08 | BTIG, LLC |
| 2023-11-02 | Dubensky Thomas W. | Officer, Director | 30,000 | 2023-10-25 | Merrill Lynch |
Showing 1–3 of 3 filings